Two Peptides Derived from the Nerve Growth Factor Precursor Are Biologically Active by Dicou, Eleni et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/97/01/389/10 $2.00
The Journal of Cell Biology, Volume 136, Number 2, January 27, 1997 389–398 389
 
Two Peptides Derived from the Nerve Growth Factor
Precursor Are Biologically Active
 
Eleni Dicou,* Beth Pflug,
 
‡
 
 Marilyn Magazin,
 
§
 
 Thérèse Lehy,
 
i
 
 Daniel Djakiew,
 
‡
 
 Pascual Ferrara,
 
§
 
Véronique Nerrière,* and Douglas Harvie*
 
*Institut National de la Santé et de la Recherche Médicale U298, Centre Hospitalier Universitaire, Angers 49033, France; 
 
‡
 
Department of Cell Biology, Georgetown University Medical Center, Washington DC, 20007; 
 
§
 
Sanofi Recherche, 31676 
 
Labège, France; and 
 
i
 
Institut National de la Santé et de la Recherche Médicale U10, Hôpital Bichat, 75877 Paris, Cedex 18, 
France
 
Abstract. 
 
This report provides evidence that the prore-
gion of the NGF precursor protein contains two novel 
bioactive peptides. The presence of pairs of basic amino 
acid (aa) residues in the NGF proregion suggests that 
two or three peptides other than NGF may be gener-
ated by proteolytic cleavage. Synthetic peptides of 29 
aa (LIP1) and 38aa (LIP2) corresponding to the se-
quences 
 
2
 
71 to 
 
2
 
43 and 
 
2
 
40 to 
 
2
 
3 of the proNGF, re-
spectively, were used in this study. ELISA specific for 
these two peptides revealed their presence in the rat in-
testine. LIP1 was localized by immunohistochemistry in 
endocrine cells of the intestinal epithelium, and LIP2 
was immunoprecipitated from an intestinal extract. We 
also provide evidence for the presence of specific re-
ceptors for LIP2 in several cell lines. Scatchard analysis 
indicated the presence of a low affinity binding site with 
a K
 
d
 
 of 
 
z
 
10
 
2
 
7
 
 M and a high affinity binding site of 10
 
2
 
9
 
 
M. Cross-linking studies revealed receptor forms of 
about 140 kD and 93 kD in a prostatic adenocarcinoma 
cell line.
LIP1 and LIP2 induced rapid F-actin redistribution in 
PC12 cells within 2 min of incubation, which suggests a 
role of LIP1 and LIP2 in the process of neurite out-
growth. Furthermore, both propeptides induced rapid 
tyrosine phosphorylation of the Trk protein in both 
prostatic adenocarcinoma cells and PC12 cells, thus im-
plicating 
 
trk
 
 in their mechanism of action. These results 
support our hypothesis that two peptides within the 
NGF precursor protein are biologically active.
 
N
 
GF and the NGF family of neurotrophins regulate
the survival and differentiation of neurons in the
peripheral and central nervous systems (Thoenen,
1991; Meakin and Shooter, 1992). The nucleotide sequence
of the NGF cDNA, isolated from the mouse submaxillary
gland (MSG)
 
1
 
 contains two potential methionine initiation
codons that can give rise to two precursor molecules: a long
form of 
 
z
 
34 kD and a short form of 27 kD (Scott et al.,
1983; Ullrich et al., 1983). Precursor forms of 
 
z
 
31 and 24 kD
have been observed in vivo (Dicou et al., 1986; Dicou,
1992). The NGF moiety is situated at the COOH terminus
and is flanked by dibasic amino acid (aa) processing sites.
Formation of the mature 118aa NGF peptide requires pro-
teolytic processing at both ends. Two other dibasic amino
acids, representing potential processing sites, exist within
the proregion that may generate two peptides, 29aa (LIP1)
and 38aa (LIP2), from the short precursor and an addi-
tional 89aa peptide from the long precursor (Fig. 1). Libera-
tion of the NH
 
2
 
-terminal pre-propeptide from the long
precursor was detected in vitro after digestion of the trans-
lation products of NGF mRNAs with 
 
g
 
-NGF, a trypsin-
like subunit involved in the maturation of the MSG NGF
(Dicou, 1989). In addition, in vitro mutagenesis studies
suggested that two domains, situated within the proregion
 
2
 
53 to 
 
2
 
26 and 
 
2
 
8 to 
 
2
 
2, may be important for the ex-
pression of active NGF (Suter et al., 1991).
It remained an open question whether the putative
proNGF peptides have any biological role or whether they
exist in vivo. To investigate these aspects, the two propep-
tides, LIP1 and LIP2, were chemically synthesized, and re-
spective antibodies were raised in rabbits. The antibodies
were used to develop specific ELISA. The synthetic pep-
tides were used to characterize potential biological roles as
well as to search for the presence of specific receptors.
 
Materials and Methods
 
LIP Peptides
 
Various peptides were purchased from Sigma Chemical Co. (St. Louis,
MO). LIP1, a 29aa peptide, was synthesized by Neosystem SA (Stras-
bourg, France). LIP2, a 38aa synthetic peptide, was synthesized by Penin-
sula Labs. Europe, Ltd. (St. Helens, UK) Both peptides were purified to
 
.
 
95% purity, as estimated from the HPLC profile and verified by thin
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Abbreviations used in this paper
 
: aa, amino acid; ChAT, choline acetyl-
transferase; DRG, dorsal root ganglia; F-actin, filamentous actin; MSG,
mouse submaxillary gland; NT, neurotrophin; PS, proteolytic site.
  
The Journal of Cell Biology, Volume 136, 1997 390
 
layer chromatography, amino acid analysis, HPLC (2 systems), and mass
spectrometry. No significant homologies were found in the protein bank,
NBRS (using the BLAST program), between these peptides and any
known protein sequences other than to NGF precursor-related sequences.
 
Antibodies
 
Rabbits were immunized with peptides (1 mg) coupled to keyhole limpet
hemocyanin (6 mg) with benzoquinone (Dicou et al., 1988). ELISA using
immunoplates coated with 2 
 
m
 
g/ml of peptide in 0.1 M carbonate buffer,
pH 9.2, was employed to test for the presence of specific antibodies in the
sera, as described elsewhere (Dicou et al., 1989). The titer of the antipep-
tide antibodies was estimated to be 
 
>
 
1:200,000.
 
ELISA
 
Rabbit IgGs were purified by passage of polyclonal antibodies against
LIP1 or LIP2 over a protein A column. ELISA plates (Nunc, Rostkilde,
Denmark) were coated with 15 
 
m
 
g/ml purified rabbit IgG in 0.1 M carbon-
ate buffer, pH 9.2, for 4 h at 37
 
8
 
C. Plates were washed five times with PBS-
0.01% Tween. 100 
 
m
 
l of sample of either diluted synthetic peptide or tis-
sue extract was pipetted into each well and incubated overnight at 4
 
8
 
C.
Plates were then washed five times with PBS-0.01% Tween. Tissue ex-
tracts were tested at several serial dilutions. Part of the purified rabbit IgG
was biotinylated with NHS-LC–Biotin (sulfosuccinimidyl-6-(biotinamido)
hexanoate; Pierce, Rockford, IL) according to the manufacturer’s instruc-
tions and used as a secondary antibody, at a concentration of 5 
 
m
 
g/ml in
PBS-0.01% Tween–0.5% gelatin (PTG), for 2 h at 37
 
8
 
C. In specificity con-
trols, unbiotinylated IgGs were added together with biotinylated IgGs at a
ratio of 5:1, respectively. Plates were washed five times and incubated for
2 h at 37
 
8
 
C with avidin–peroxidase (Dako Corp., Carpinteria, CA) at
1:5,000 dilution in PTG. The reaction was visualized by adding 2,2
 
9
 
-Azino
bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS; 1 mg/ml) as peroxidase
substrate. The optical density was determined in a multiscan analyzer at
an absorbance of 405nm. LIP1 and LIP2 values were calculated from ab-
sorbance data within the linear range of the calibration curve (Fig. 2) after
subtracting the nonspecific background readings. This was done by includ-
ing an excess of unbiotinylated antibody as the second antibody. Values are
expressed in pg/mg protein of the tissue extract after centrifugation.
Chimeric 
 
b
 
-galactosidase pre-proNGF was produced in 
 
Escherichia
coli
 
, harboring a bacterial vector with the fused preproNGF cDNA, and
purified from the soluble fraction after cell lysis, as previously described
(Dicou et al., 1989).
NGF was quantified with a two-site enzyme immunoassay using the
monoclonal anti–mouse-
 
b
 
 (2.5S) NGF antibody 27/21 (Boehringer Mann-
heim Biochemicals, Mannheim, Germany), as described previously (Mac-
Grogan et al., 1992). From the standard curve, using purified mouse NGF,
concentrations as low as 0.2 pg/well can be measured reproducibly.
 
Cell Extracts and Radiolabeling
 
Tissues were dissected from male Wistar rats (250 g) and homogenized with
a Polytron homogenizer in 0.1 M borate buffer, pH 8.5, containing 1 mM
phenylmethylsulfonylfluoride and 1 mM tosyl-
 
l
 
-lysine chloromethyl ketone
(3 ml/g wet tissue). Homogenates were centrifuged at 100,000 
 
g
 
 for 30 min,
and the clarified supernatants were assayed by the specific ELISA and for pro-
tein content using a protein assay (Bio-Rad Laboratories, Inc., Richmond, CA).
About 100 
 
m
 
g of a rat intestinal extract that contained high LIP2 levels
was radiolabeled with 50 
 
m
 
Ci of 
 
35
 
S-labeling reagent (Amersham Intl.,
Buckinghamshire, England), according to the manufacturer’s instructions,
for 30 min on ice. Subsequently, an additional 200 
 
m
 
g of extract was
added, and incubation was continued for 30 min on ice. The reaction was
stopped with 100 
 
m
 
l of 0.2 M glycine. In parallel, 10 
 
m
 
g of synthetic pep-
tide was labeled with 50 
 
m
 
Ci of 
 
35
 
S-labeling reagent for 1 h on ice, and the
reaction was stopped as above.
 
Immunoprecipitations
 
Half of the radiolabeled intestinal extract and 
 
z
 
2 
 
m
 
g of the labeled peptide
were incubated with 10 
 
m
 
l of either anti peptide or preimmune serum and
100 
 
m
 
l of protein-A Sepharose, as previously described (Dicou, 1989). Im-
munoprecipitated complexes were analyzed by 18% SDS-PAGE (Laemmli,
1970) and subsequently by autoradiography.
 
Immunohistochemistry
 
Tissue samples of small intestine from adult Wistar rats were fixed in
Bouin’s solution at room temperature or in 4% paraformaldehyde in
phosphate-buffered saline (0.1 M, pH 7.4) at 4
 
8
 
C for 18–24 h. They were
routinely processed for dehydration, followed by paraplast embedding,
and cut in 4-
 
m
 
m thick sections. Before immunoreaction, endogenous per-
oxidase activity was removed by dipping sections into 0.3% H
 
2
 
O
 
2
 
 in meth-
anol for 30 min. Nonspecific binding of IgG was blocked by incubation in
10% normal goat serum. Thereafter, sections were incubated for 16 h at
4
 
8
 
C with anti-LIP1 serum, diluted 1:16, or with anti-LIP2, diluted 1:150–
200. Sections were then incubated with goat biotinylated anti–rabbit IgG,
diluted 1:200 for 30 min, and finally with the avidin–biotin complex, di-
luted 1:100 for 1 h (ABC Vectastain kit; Vector Labs Inc., Burlingame,
CA). Negative controls were obtained by incubating tissue sections with
preimmune serum. Specificity of the staining was checked by overnight
preincubation of the anti-LIP1 or anti-LIP2 antiserum with 10, 20, or 40
 
m
 
g of the homologous peptide/ml of diluted antisera.
 
Cell Lines
 
The human prostatic adenocarcinoma cell line, B5, derives from the tu-
morigenic DU-145 cell line after transfection with a normal retinoblas-
toma gene. This resulted in the loss of the capacity of B5 cells to form tu-
mors (Bookstein et al., 1990). B5 cells were grown in DME with 10% FCS.
PC12 cells (purchased from the American Type Culture Collection
[ATCC]) and PC12 6-24 (Hempstead et al., 1992), overexpressing TrkA
by 10–15-fold (gift of Dr. D. Kaplan, Montreal Neurological Institute,
Montreal, Quebec, Canada), were grown in RPMI-1640 (GIBCO BRL
Laboratories, Grand Island, NY) supplemented with 10% horse serum
(HS) and 5% FCS. SH-SY5Y cells were grown in RPMI-1640 medium
supplemented with 12% FCS, L-929 cells in DME supplemented with 5%
FCS, Ros cells in F12 Ham’s supplemented with 10% FCS, 6-23 cells in
DME supplemented with 12% HS and 2.5% FCS, and Vero cells in
RPMI-1640 supplemented with 10% FCS. For binding studies, cells were
washed in PBS, scraped with a rubber policeman, collected by centrifuga-
tion, and resuspended in binding buffer.
 
Iodination
 
LIP2 (5 
 
m
 
g) was iodinated using 10 
 
m
 
g of chloramine-T (Sigma Chemical
Co.) and 0.5–1 mCi of Na[
 
125
 
I], sp act 15 mCi/
 
m
 
g (Amersham Intl.) in a to-
tal reaction volume of 50 
 
m
 
l in 0.25 M sodium phosphate buffer, pH 7.5, for
8 min at room temperature. The reaction was stopped with 500 
 
m
 
g of so-
dium metabisulphite, and unreacted iodide was removed by gel filtration
on a PD10 column (Pharmacia Fine Chemicals, Piscataway, NJ) pre-equil-
ibrated in PBS, 0.01% Tween-20. Specific activity was 300–500 cpm/fmol.
 
Binding Assay
 
Approximately 0.5–1 
 
3
 
 10
 
6
 
 cells were incubated in binding buffer (PBS,
0.1% BSA), together with the appropriate concentrations of the iodinated
peptide to give a final volume of 50 
 
m
 
l, in a 96-well, round-bottomed plate,
with agitation, at 4
 
8
 
C or at room temperature. Samples were then layered
Figure 1. Schematic representation of the NGF precursor as de-
duced from the cDNA clone. The dark box is the NGF peptide.
Arrows indicate possible proteolytic sites. AUG is the initiation
methionine codon. LIP1 corresponds to the sequence between
271 to 243 and LIP2 corresponds to the sequence between 240
to 23 of the rat NGF precursor. 
Dicou et al. 
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on a cushion of 150 
 
m
 
l of a 90% dibutyl phthalate and 10% mineral oil
mixture (both Sigma Chemical Co.) in 400-
 
m
 
l microfuge tubes and centri-
fuged in a microfuge centrifuge (Beckman Instruments, Inc., Fullerton,
CA) for 45 s. The tubes were frozen in liquid nitrogen and the tips (bound
fraction) as well as the rest of the tube (free fraction) were removed and
counted in a gamma counter. Nonspecific binding was determined in the
presence of a 400–1,000-fold excess of peptide. Curve fittings were per-
formed using the Graphit data analysis program (Erithacus Software Ltd.,
Staines, UK). In competition experiments, 
 
z
 
10
 
6
 
 B5 and SH-SY5Y cells
were preincubated with 2 
 
m
 
M of each competitor for 1 h at 4
 
8
 
C. [
 
125
 
I]LIP2
was added at 10 nM and incubation continued. Specifically bound radioac-
tivity was determined as above.
 
Cross-linking
 
About 10
 
7
 
 cells were incubated in 200 
 
m
 
l binding buffer, containing 100 nM
 
125
 
I-LIP2, for 2 h at 4
 
8
 
C, either with or without 400-fold excess peptide.
Cells were washed extensively in ice cold PBS, resuspended in 200 
 
m
 
l PBS,
and incubated with 20 mM 1-Ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDC; Pierce) for 30 min at room temperature. Cells were then
washed twice in PBS and solubilized in Laemmli electrophoresis buffer.
Proteins were resolved by 10% SDS-PAGE, followed by autoradiography
on XAR-5 films (Laemmli, 1970).
 
Fluorescent Microscopy
 
PC12 and B5 cells were seeded into RPMI-1640 medium containing 1%
HS in 15-ml slide flasks (coated with poly-D-lysine for PC12 cells). After
18 h of culture, cells were incubated for 2 min at 37
 
8
 
C in the presence of
10
 
2
 
7
 
, 10
 
2
 
8
 
, or 10
 
2
 
9
 
 M peptide concentration or 100 ng/ml NGF. After
washing with PBS, pH 7.4, cells were fixed with 3% paraformaldehyde
(Merck Chemical Div., Rahway, NJ) for 20 min, washed, permeabilized in
0.1% Triton X-100 for 2 min, and then stained with a phallacidin–BO-
DIPY or a phalloidin–rhodamine conjugate (Molecular Probes, Inc., Eu-
gene, OR), using procedures similar to those described by Wulf et al. (1979).
Slides were mounted with Vectashield medium (Vector Labs Inc.) and
photographed with a microscope (Dialux 20; E. Leitz Inc., Rockleigh, NJ).
 
Neurite Outgrowth Bioassay
 
Dorsal root ganglia (DRG) were dissected from a 9-d-old chick embryo
and cultured in the presence of 10
 
2
 
7
 
, 10
 
2
 
8
 
, and 10
 
2
 
9
 
 M LIP1, LIP2, or with
10 ng of mouse NGF, as previously described (Dicou et al., 1993).
 
Trk Phosphorylation
 
The PC12 overexpressors of TrkA and B5 cells were grown to confluency
in 150-mm plates. Cells were stimulated for 5 min with LIP1 or LIP2 (10
 
2
 
9
 
or 10
 
2
 
7
 
 M in serum containing medium for LIP1 or 0.02% Tween for
LIP2) or NGF (200 ng/ml, Genentech, Inc., South San Francisco, CA) and
treated as previously described (Pflug et al., 1995). Cell lysates were im-
munoprecipitated with 4 
 
m
 
l of panTrk-21 antibody generated against the
14 COOH-terminal residues of the TrkA protein (Cephalon Inc., West
Chester, PA). Immunoprecipitates were resolved by 7.5% SDS-PAGE
and transferred onto a 0.2-
 
m
 
M nitrocellulose membrane. Blots were probed
overnight at 4
 
8
 
C with an antiphosphotyrosine antibody conjugated to
horseradish peroxidase (RC-20; Transduction Laboratories, Lexington, KY)
at a 1:2,500 dilution in TBS supplemented with 0.1% Tween (TBST). Im-
munoreactivity was observed using enhanced chemiluminescence (ECL kit;
Amersham Corp., Arlington Heights, IL). Blots were stripped (50 mM
Tris, pH 6.5, 150 mM NaCl, and 2% 
 
b
 
-mercaptoethanol) at 70
 
8
 
C for 1 h and
reprobed overnight at 4
 
8
 
C with panTrk-203 antibody (Kaplan et al., 1991) at
a 1:5,000 dilution in TBST. Goat anti–rabbit horseradish peroxidase–conju-
gated secondary antibody (Boehringer Mannheim Biochemicals) was used at
a 1:20,000 dilution in TBST for 1 h at room temperature, followed by ECL.
 
Results
 
Detection of LIP1 and LIP2 by ELISA
and Immunohistochemistry
 
The double-sandwich ELISA, specific for the two pep-
tides, consisted of first coating microplates with purified
polyclonal antibodies against LIP1 or LIP2. The sample
containing appropriate dilutions of either the peptide solu-
tion or cell extract to assay was then added to form the
primary antibody–antigen complex. As a secondary anti-
body, biotinylated polyclonal antibodies against LIP1 or
LIP2 were used. The second antibody was revealed by the
addition of avidin peroxidase, followed by the peroxidase
substrate. The amount of LIP1 or LIP2 was calculated from
a calibration curve that uses chemically synthesized LIP1
or LIP2 as a standard (Fig. 2). The detection limit for LIP1
is 
 
z
 
7 pg/well and for LIP2, 
 
z
 
4 pg/well. A specificity test
was performed by the simultaneous addition of biotiny-
lated and unbiotinylated antibodies as second antibody.
This resulted in the extinction of the signal (Fig. 2).
The specificity of the ELISA was assessed against a
panel of peptides and proteins. There was no cross-reac-
tion against NGF, somatostatin, bradykinin, vasopressin,
leucine enkephalin, methionine enkephalin, neurotensin,
bombesin, angiotensin II, 
 
a
 
-melanocyte stimulating hor-
mone, and a peptide that reproduces the sequence 
 
2
 
163 to
 
2
 
139 of the proNGF. In addition, there was no cross-reac-
tion between LIP1 and LIP2 (data not shown).
In order to further verify that values measured by the
ELISA assays correspond to the free peptides rather than
proNGF sequences, the following control experiments
Figure 2. Calibration curve of the ELISA specific for the pep-
tides. HPLC-purified synthetic peptides were used. The curve
shows the linearity and sensitivity of the ELISA for LIP1 ( )
and LIP2 ( ). Peptide concentrations are in pg/well. The signal
is strongly diminished in the presence of excess unbiotinylated
antibodies (dark symbols).The Journal of Cell Biology, Volume 136, 1997 392
were performed. We have previously reported the synthe-
sis of a chimeric b-galactosidase pre-proNGF protein in
Escherichia coli (Dicou et al., 1989). LIP1 antibodies failed
to cross-react with the chimeric pre-proNGF, while LIP2
antibodies cross-reacted with the pre-proNGF protein but
to a lesser extent than with the peptide. The sensitivity of
the ELISA was estimated to be about 25 times higher for
LIP2 as compared to the precursor protein at equimolar
concentrations of LIP2 and chimeric pre-proNGF. These
in vitro results were also corroborated from measurements
of LIP1 and LIP2 in extracts of the male MSG. The NGF
mRNA content in this gland represents z0.1% of the total
mRNA, the highest in any other tissue. No LIP1 was de-
tectable in these extracts, while LIP2 was estimated at
about 2 6 0.5 pg/mg protein (n 5 4).
Using these ELISA tests, we examined several rat pe-
ripheral tissues for the presence of immunoreactive mate-
rial (Table I). Most of the tissues examined was negative.
Heart, spleen, and brain tissues, where expression of NGF
mRNA is high, were negative. Some LIP2 was detectable
in low amounts in the liver. The tissue that contained con-
siderable levels of both peptides was the intestine. LIP2 like
immunoreactive material was present in greater amounts
as compared to LIP1. LIP1 and LIP2 seemed to be distrib-
uted along the small intestine, since extracts prepared sep-
arately from the duodenum, jejunum, and ileum all con-
tained both peptides.
NGF was also measured in the intestinal extracts of two
adult rats using a two site immunoassay, employing the
monoclonal antibody 27/21 with a detection limit for NGF
at about 0.2 pg/well. The estimated NGF was 0.15 6 0.02
pg/mg protein (n 5 4) for one rat and 0.18 6 0.05 pg/mg
protein (n 5 4) for the second rat. The thermostability of
the ELISA cross-reactive material was tested by heating
intestinal extracts at 1008C for 1 h at pH 2. LIP1 and LIP2
activities were completely recovered, thus suggesting that
they are temperature and acid resistant.
In order to determine whether food uptake physiologi-
cally influences mucosal content of LIP1 and LIP2, intesti-
nal extracts from normally fed rats and from rats starved
for 48 h were assayed for LIP1 and LIP2. There was a
decrease of about 70 6 5% (n 5 4) of LIP1 and 96 6 4%
(n 5 4) of LIP2 in extracts from food-deprived rats, as
compared to their counterpart normally fed rats. In con-
trast, there was no change in NGF levels. NGF in the in-
testinal extract of a normally fed rat was estimated at
z0.10  6 0.01 pg/mg protein (n 5 4), as compared to 0.12 6
0.01 pg/mg protein (n 5 4) found in a starved rat.
Neither LIP1 nor LIP2 was detectable in an extract pre-
pared from a brain hemisphere. However, some LIP2
was detectable in an extract prepared separately from
the cortex (1.2 6 0.1 pg/mg protein, n 5 4), hippocampus
(1.5 6 0.3 pg/mg protein, n 5 4), and septum (5 6 1 pg/mg
protein, n 5 4), while an extract of the cerebellum was
negative. LIP1 was undetectable in any of the brain re-
gions examined.
Immunoprecipitations from an intestinal extract that
contained 140 pg/mg protein of LIP2 and 19 pg/mg protein
of LIP1 (not included in Table 1) yielded a band (Fig. 3,
lane 3) comigrating with the immunoprecipitated synthetic
LIP2 peptide (lane 1). This band was absent in immuno-
precipitates with preimmune serum (lane 4). We failed to
detect immunoprecipitated LIP1, probably due to its
lower levels.
Immunohistochemistry of tissue sections of the rat intes-
tine localized LIP1 immunoreactivity in endocrine cells
(Fig. 4). These cells were recognized by their ovoid or py-
ramidal shape, their position along the basement mem-
brane, and the presence of a thin, cytoplasmic process
extending to the gut lumen. They were relatively well rep-
resented, especially in the duodenal mucosa, and they
were distributed both in villi and crypts, with a higher fre-
Table I. Measurements of LIP1 and LIP2 by ELISA in
Rat Tissues
LIP1 LIP2
Heart 22
Spleen 22
Lung 22
Kidney 22
Liver 2 1.7 6 1
(n 5 4)
Intestine 8 6 5* 67 6 35*
(n 5 15) (n 5 15)
Brain 2‡ 2‡
Pancreas 22
Values are in pg/mg protein.
2Levels below the limit of detection. Negative tissues were obtained from two rats,
and a total of four independent determinations were performed.
*Results were obtained from five rats.
‡Extract prepared from a brain hemisphere.
Figure 3. Immunoprecipitation of LIP2 peptide from a rat intes-
tinal extract. Radiolabeled LIP2 synthetic peptide was immuno-
precipitated with anti-LIP2 (lane 1) or with preimmune serum
(lane 2). Radiolabeled rat intestinal extract was immunoprecipi-
tated with anti-LIP2 serum (lane 3) or with preimmune serum
(lane 4). Immunoprecipitates were fractionated by 18% SDS-
PAGE, followed by autoradiography for 20 wk. Molecular
weight markers are BSA (68 kD), ovalbumin (45 kD), a-chymo-
trypsinogen A (25 kD), and LIP2 (4.2 kD).Dicou et al. Biologically Active proNGF Peptides 393
quency in the latter. Staining of LIP1-immunoreactive en-
docrine cells was decreased by prior absorption of antise-
rum with 10 mg/ml of homologous peptide and completely
abolished by prior absorption with 20 mg/ml. Two poly-
clonal anti-NGF sera tested in parallel did not stain these
endocrine cells, whereas they positively stained the convo-
luted tubules of the MSG, as previously described (Dicou
et al., 1988). Weak to moderate anti-LIP2 immunoreactiv-
ity was found in epithelial cells of Brünner’s glands and in
villi and crypt cells. There was no staining of these cells
with the corresponding preimmune serum, but preabsorp-
tion of the antiserum with the homologous peptide did not
abolish the signal.
Binding of 125I-LIP2 to Cell Lines
We screened several cell lines for the presence of recep-
tors for LIP2 rather than LIP1, because LIP2 has three his-
tidine residues, whereas LIP1 has no tyrosine or histidine
residues for radioiodination. The prostatic adenocarci-
noma cell line, B5, was previously shown to synthesize and
secrete NGF (MacGrogan et al., 1992). Specific binding of
125I-LIP2 was detected in B5 cells in a time and tempera-
ture dependent manner. At room temperature (z258C)
the peptide bound rapidly, reaching equilibrium in 30 min,
whereas at 48C it reached equilibrium in 2 to 3 h. Scat-
chard plot analysis showed the presence of a low affinity
binding site, with a Kd of 48 6 11 nM and 46,300 6 6400
sites/cell (Fig. 5). Nonspecific binding represented less
than 30% of total binding. In addition, a high affinity bind-
ing site with a Kd of 2.8 6 0.1 nM and 7,057 6 409 sites/cell
was also detectable (Fig. 6). The low affinity binding con-
stant obtained from analysis of Scatchard plots was also
corroborated by displacement experiments in which cells
were incubated simultaneously with a constant amount of
125I-LIP2 (10 nM) and increasing amounts of nonradioac-
tive LIP2, up to 2 mM for 2h at 48C. The apparent Kd for
the unlabeled peptide was about 2–4 3 1027 M.
Other cell lines that bound 125I-LIP2 included PC12 (rat
pheochromocytoma) cells, 6-23 (rat medullary thyroid car-
cinoma) cells, SH-SY5Y (human neuroblastoma) cells, and
HeLa (human cervical epithelioid carcinoma) cells. We
failed to detect the high affinity component in SH-SY5Y
and in HeLa cells. In the positive cell lines, the low affinity
constant ranged between 1027–1028 M and z50,000–
140,000 sites/cell, whereas the high affinity component
Figure 4. Localization of LIP1 immunoreactivity in the rat intestine. (A) General view of duodenal mucosa (Bouin-fixed tissue) show-
ing LIP1-immunoreactive endocrine cells localized in crypt and villi (arrows). Nuclei were counterstained with Mayer’s glychemalun.
Bar, 20 mm. (B and C) Details of other LIP1-positive endocrine cells, one cell in a villus (B, arrow; this cell exhibits a characteristic cyto-
plasmic extension to the gut lumen) and two cells in crypts. Bar, 10 mm.The Journal of Cell Biology, Volume 136, 1997 394
ranged between 0.5–2 3 1029 M and 1000–7000 sites/cell.
In contrast, several cell lines, including Vero (African
green monkey kidney) cells, Ros (rat osteosarcoma), and
L-929 (mouse fibroblast) cells, did not bind 125I-LIP2.
The specificity of the LIP2 binding was further investi-
gated by competition with various peptides and proteins,
as described in Materials and Methods. No significant in-
hibitory effect was exerted by epidermal growth factor,
methionine enkephalin, leucine enkephalin, vasopressin,
vasoactive intestinal peptide (VIP), substance P, neuro-
tensin, bombesin, cytochrome c, ubiquitin, aprotinin, leu-
peptin, pepstatin A, a2-macroglobulin, somatostatin and
a-melanocyte stimulating hormone (data not shown).
However, some inhibition of binding was obtained with
LIP1 (40 6 5% inhibition; two independent determina-
tions) and to a lesser extent with NGF (25 6 3% inhibi-
tion; two independent determinations).
Cross-linking studies of 125I-LIP2 bound to B5 cells
showed the presence of a 145–150–kD species comigrating
with the medium neurofilament protein subunit used as
external marker and a 97-kD species comigrating with phos-
pholipase B in SDS-polyacrylamide gels (Fig. 7). Given a
molecular weight of about 4 kD for LIP2, this would sug-
gest receptor forms of about 140–145 kD and 93 kD.
Induction of F-actin Redistribution by LIP1 and LIP2 
in PC12 Cells
One of the earliest morphological events induced by NGF
in PC12 cells is the redistribution of filamentous actin
(F-actin) which occurs within minutes after the addition of
the growth factor (Connolly et al., 1979; Paves et al., 1990).
The formation of ruffles, accompanied by the redistribu-
tion of F-actin, may be one of the earliest steps in the pro-
cess of neurite outgrowth in PC12 cells. We tested the pos-
sible effect of the peptides on the redistribution of F-actin.
The two peptides induced striking morphological changes
in PC12 cells within 2 min (Fig. 8) at all three peptide con-
centrations tested (1027, 1028, and 1029 M). Fluorescent
phalloidin specific for F-actin strongly labeled the stellate
shapes generated in response to LIP1 and LIP2 at the cell
periphery (Fig. 8 C, D). The distribution of F-actin into in-
Figure 5. Low affinity binding of [125I]LIP2 to B5 cells. (A) In-
creasing concentrations of 125I-LIP2 were incubated for 2 h at 48C
with B5 cells (106 cells in 50 ml), and the bound and free fractions
were determined as described in Materials and Methods. Specific
binding is shown after subtraction of nonspecific binding from to-
tal binding. (B) Scatchard plot of the specific binding component.
Curve fitting was as in Materials and Methods (estimated Kd 5
48 6 11 nM; Bmax 5 46,300 6 6400 sites/cell).
Figure 6. High affinity binding of 125I-LIP2 to B5 cells. Experi-
mental conditions are as in Fig. 4. (A) Specific binding. (B) Scat-
chard plot of the specific component (estimated Kd 5 2.8 6 0.1 nM;
Bmax 5 7057 6 409 sites/cell).Dicou et al. Biologically Active proNGF Peptides 395
tensely fluorescent spikes in the cell periphery was similar
but not identical to the more abundant ruffling induced by
NGF (Fig. 8 B). Similar results were observed in PC12
cells that overexpress TrkA (data not shown). As a con-
trol, [Tyr8] bradykinin was tested at 1026 and 1027 M and
had no effect. Moreover, the effect of LIP1 and LIP2 is
cell specific, since neither NGF nor the peptides induced
F-actin rearrangement in B5 cells (Fig. 8 F). However, nei-
ther LIP1 nor LIP2 was able to induce neurite outgrowth
either in PC12 cultures or in chick embryo DRG ganglia at
1027–1029 M concentration, while dense neurite outgrowth
was observable in NGF-treated PC12 cells and DRGs (data
not shown).
Induction of Tyrosine Phosphorylation of the Trk 
Protein by LIP1 and LIP2 in PC12 and B5 Cells
The Trk protein, a 140-kD tyrosine kinase, was demon-
strated to be the high affinity NGF receptor. NGF was
shown first to trigger rapid phosphorylation and also to
bind directly to Trk (Kaplan et al., 1991; Klein et al., 1991).
Therefore, we looked for the possible induction of ty-
rosine phosphorylation of Trk by the two peptides. B5
cells and PC12 cells that overexpress TrkA were exposed
to LIP1 or LIP2 for 2 min, and cell lysates were immuno-
precipitated with an antibody generated against the
COOH-terminal Trk peptide. Immunoprecipitates were
subsequently probed with anti-phosphotyrosine (Ptyr) an-
tibodies. Indeed, Trk was rapidly phosphorylated after ad-
dition of 1029 M LIP1 or LIP2 in both PC12 and B5 cells,
although peptide induction was less potent than NGF in
PC12 cells. Fig. 9 shows a typical result which was repro-
duced in five independent experiments. There was no or
little induction of Trk phosphorylation at 1027 M peptide
concentration in B5 cells (Fig. 9) nor in PC12 cells (data
not shown).
Discussion
Putative Peptides from NGF and
Neurotrophin Precursors
Peptide–hormone precursors are known to undergo post-
translational cleavage to yield several biologically active
peptides from one precursor molecule (Harris, 1989). It is
generally accepted that the recognition sequence for en-
doproteolysis is a doublet of basic amino acids which
bracket the peptide. The NGF precursor sequence con-
tains four such sites (Fig. 1). Proteolysis at the proteolytic
site (PS) 3 and PS4 liberates the NGF protein. Our work-
ing hypothesis was that processing may also occur at PS1
and PS2 in certain tissues, to yield two additional peptides
of 29aa (LIP1) and 38aa (LIP2) from the short NGF pre-
cursor, which starts at the second initiator methionine
codon and is the predominant precursor form in most tis-
sues (Edwards et al., 1986). An NH2-terminal 89aa peptide
may also be generated from the long precursor, which
starts at the first methionine codon and is the predominant
form in the MSG. The neurotrophins (NT), brain derived
neurotrophic factor (BDNF) (Leibrock et al., 1989), NT-3
(Maisonpierre et al., 1990), NT-4 (Hallböök et al., 1991),
and NT-5 (Berkemeier et al., 1991; Ip et al., 1992) share
50–55% homology with NGF and are all synthesized from
long precursor molecules. PS1 and PS2 are absent in pro-
BDNF, and its corresponding 240 to 23 region shares
only about 24% homology with LIP2. The NT-3 precursor
lacks PS1, but PS2 and PS3 are conserved. Thus a LIP2-
like peptide could be potentially generated from proNT-3,
but it shares only about 31% homology with LIP2. The
proNT-4 lacks both PS1 and PS2, and its corresponding
240 to 23 region shares about 26% homology with LIP2.
The proNT-5 also lacks PS1 and PS2, and the correspond-
ing 240 to 23 region shares about 21% homology with
LIP2. Thus LIP1 and LIP2 may only be generated from
the precursor sequence of proNGF.
LIP1 and LIP2 are Predominantly Expressed in
the Intestine
The surprising finding was the detection of significant lev-
els of LIP2 and, to a lesser extent, LIP1 in extracts of the
intestine, whereas no LIP1 and low levels of LIP2 were de-
tected in the MSG. Immunoprecipitation of LIP2 from
an intestinal extract also indicates that the ELISA immu-
noreactive material is the free peptide. Furthermore, im-
munohistochemical evidence for the localization of LIP1
in intestinal endocrine cells that did not show any NGF
immunoreactivity suggests a distinct role for this peptide
in the intestine. The presence of LIP1 and LIP2 in the in-
testine was unexpected, because low levels of NGF protein
were measured by the two site NGF ELISA in this tissue.
More elevated NGF levels estimated at z1 pg/mg protein
were previously reported in the rat intestine (Westkamp
and Otten, 1987). A low level of NGF synthesis has also
been detected in vitro in intestinal epithelial cell lines (Vari-
lek et al., 1995). The considerable levels of LIP1 and LIP2
in the intestine, as compared to their low levels in the
MSG, suggests a differential expression of the two propep-
tides in these tissues.
No LIP1 or LIP2 was detected in whole brain extracts.
Figure 7. Characterization of
LIP2 receptors by cross-link-
ing. About 107 B5 cells were
incubated for 2 h at 48C with
100 nM 125I-LIP2 in the ab-
sence (2) or presence (1) of
excess unlabeled peptide. Af-
ter washing and cross-link-
ing with EDC, cells were sub-
jected to electrophoresis as
described in Materials and
Methods. Arrows indicate
cross-linked species. Exter-
nal markers are: neurofila-
ment heavy subunit (200
kD), neurofilament medium
subunit (145 kD), phospholi-
pase B (97 kD), neurofilament
light subunit (70 kD), and
carbonic anhydrase (29 kD).The Journal of Cell Biology, Volume 136, 1997 396
In general, most neuropeptides are found peripherally and
to a much lesser extent in brain extracts because of hetero-
geneity of the different regions of the brain (Lynch and
Snyder, 1986). LIP2 was detectable in certain forebrain re-
gions (cortex, hippocampus, and septum), however, other
regions of the brain should be examined either by his-
tochemistry or by immunoassay for the presence of these
peptides. In a past study using purified antibodies against a
shorter peptide (26aa) within the LIP1 sequence, immu-
noreactivity was detected in several regions of the brain,
localizing within neurons in the cortex, hippocampus, and
septum; this was interpreted as proNGF-like immunoreac-
tivity (Senut et al., 1990). The question of the brain local-
ization of these peptides should be reexamined using anti-
bodies against the complete LIP1 peptide, as well as
against LIP2. Taken together, these observations suggest
that LIP1 and LIP2 may constitute peptides present in the
gut–brain axis, as it was also observed for VIP, galanin,
and somatostatin.
Evidence for Specific Receptors for LIP2
Specific binding of LIP2 was observed in several cell lines
of human and rat origin. Scatchard analysis revealed two
binding sites with different affinities for LIP2: a low affin-
ity binding site with a Kd of z1027–1028 M and a high af-
finity binding site of z1029 M. We can not exclude that
other higher affinity components may exist, but they were
undetected due to the low specific activity of the iodinated
LIP2. The high affinity LIP2 receptor, with a Kd in the na-
nomolar range, resembles receptors described for other
peptides in the digestive tract, such as VIP, galanin, and
neurotensin (Laburthe et al., 1993). The physiological sig-
nificance of the low affinity LIP2 receptor is intriguing. It
Figure 8. Effects of LIP1 and LIP2 treatment on F-actin distribution in PC12 cells and in human prostatic adenocarcinoma B5 cells.
PC12 cells (A–D) and B5 cells (E and F) were incubated for 2 min in the absence (A and E) or presence of (B) 100 ng/ml NGF, (C)
1028 M LIP1, and (D and F) 1029 M LIP2. NGF and LIP1 also had no effect on B5 cells (results not shown).Dicou et al. Biologically Active proNGF Peptides 397
may be involved in mediating LIP2 endocytosis, since up
to z40% of the bound 125I-LIP2 in acid-treated or azide-
treated B5 and SH-SY5Y cells was internalized (Harvie,
D., unpublished results). Low affinity binding was also ob-
served for several gastrointestinal peptides whose recep-
tors are coupled to G proteins (Laburthe et al., 1993).
In competition experiments, there was no significant in-
hibition of the binding of LIP2 by any of the peptides or
proteins that we tested, other than a significant inhibitory
effect by LIP1. This may suggest that LIP1 and LIP2 com-
pete for the same receptor subtype. Competition experi-
ments in the presence of 2 mM NGF and 10 nM 125I-LIP2
did not show any significant inhibition of 125I-LIP2 bind-
ing, which suggests that LIP2 does not bind at the same
sites as NGF. No transcripts coding for the low affinity
NGF receptor were detected in B5 (MacGrogan et al.,
1992). However, B5 cells express TrkA, as confirmed by
Western blot with a TrkA specific antibody (anti-TrkAin;
Pflug, B. and D. Djakiew, unpublished results), and they
may also express TrkB or TrkC. In view of the present re-
sults demonstrating that LIP1 and LIP2 induce tyrosine
phosphorylation of Trk, the possibility that these peptides
may bind directly to Trk, as does NGF, merits further ex-
amination. Our binding studies, as well as the identifica-
tion of specific molecular weight species in cross-linking
experiments, strongly suggest the presence of specific re-
ceptors for LIP2 in several cell lines and would therefore
argue in favor of a physiological role for this peptide.
Physiological Action of LIP1 and LIP2
In vitro, unlike NGF, LIP1 and LIP2 did not elicit neurite
outgrowth either in PC12 cells or in DRG explants. In
vivo, it is well established that intracerebroventricular in-
jections of NGF or NGF antibodies into neonatal rats
causes significant changes in cholinergic enzyme activities
in the septum, cortex, hippocampus, and striatum. Intra-
cerebroventricular injections of LIP1 into neonatal hy-
pothyroid rats increased choline acetyltransferase (ChAT)
and acetylcholinesterase by 24–40% in the cortex, septum,
and hippocampus. Intraventricular injections of LIP2 in-
creased ChAT by 15% only in the cortex and not in the
hippocampus or septum. However, unlike NGF, neither
LIP1 nor LIP2 had any effect on the ChAT activity of fetal
rat septal neuronal cultures (Clos and Dicou, 1997).
Since neurite formation and ChAT induction are late
events in the cellular response to exogenous signals, we
next investigated the possible effects of LIP1 and LIP2 on
early cellular events. One such event is F-actin redistribu-
tion. Upon LIP1 and LIP2 treatment, PC12 cells respond
by a rapid sequence of changes in cell surface architecture,
leading to a redistribution of F-actin, as previously shown
for NGF (Connolly et al., 1979; Paves et al., 1990). No F-actin
redistribution was observed either by the peptides or by
NGF in B5 cells. The differences in the effects between the
two cell lines may reflect differences between a neuronal
cell line (PC12) and an epithelial-like cell line (B5).
Another early cellular event is tyrosine phosphorylation
of the trk proto-oncogene product within 1 min of expo-
sure to NGF (Kaplan et al., 1991). LIP1 and LIP2 can also
induce Trk phosphorylation in B5 cells as well as in PC12
cells that overexpress TrkA. Thus activation of the Trk
tyrosine kinase receptor seems to be a possible mechanism
of signal transduction for LIP1 and LIP2. Interestingly,
Trk phosphorylation by LIP1 and LIP2 was more pro-
nounced at 1 nM than at 100 nM in B5 cells, as well as in
PC12 overexpressing TrkA. This may be due to down reg-
ulation of phosphorylation at above optimal peptide con-
Figure 9. LIP1 and LIP2 stimulated tyrosine phosphorylation of the Trk protein. PC12 cells overexpressing TrkA and B5 cells were
treated for 5 min with increasing concentrations of LIP1 and LIP2, or 200 ng/ml NGF, and lysed. Immunoprecipitation of the lysates
with panTrk-21 antibody and immunoblot analysis using an antiphosphotyrosine antibody shows phosphorylation of Trk with 1029 M
LIP1 and LIP2 and 200 ng/ml NGF in both cell lines. The blots were stripped and reprobed with panTrk-203 antibody to show equal
protein loading.The Journal of Cell Biology, Volume 136, 1997 398
centrations. A similar effect has been observed for NT-3 in-
teraction with TrkC (Tsoulfas et al., 1993) and for other
nonneurotrophin related ligand–receptor interactions (Zol-
faghari and Djakiew, 1996). A bell-shaped hormone re-
sponse curve resulting in inhibition of the transducing sig-
nal at high ligand concentrations was also observed for the
human growth hormone receptor (Fuh et al., 1992).
In summary, we provide evidence for the presence of
two propeptides derived from the NGF precursor, LIP1
and LIP2, in the intestine and the localization of LIP1 in
endocrine cells. We also demonstrate that they are biolog-
ically active, since they can induce two early events in the
cellular response: (a) F-actin rearrangement and (b)Trk
phosphorylation. Investigation for possible induction of
other intracellular signalling systems by these peptides
may reveal preferential mechanisms of activation.
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